UA114592C2 - Пептид nd2 та спосіб лікування неврологічного захворювання - Google Patents

Пептид nd2 та спосіб лікування неврологічного захворювання

Info

Publication number
UA114592C2
UA114592C2 UAA201305474A UAA201305474A UA114592C2 UA 114592 C2 UA114592 C2 UA 114592C2 UA A201305474 A UAA201305474 A UA A201305474A UA A201305474 A UAA201305474 A UA A201305474A UA 114592 C2 UA114592 C2 UA 114592C2
Authority
UA
Ukraine
Prior art keywords
peptides
methods
peptide
neurological disease
treating neurological
Prior art date
Application number
UAA201305474A
Other languages
English (en)
Inventor
Майкл Тимянскі
Ронгвен Лі
Джонатан Девід Гарман
Original Assignee
Ноно Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ноно Інк. filed Critical Ноно Інк.
Publication of UA114592C2 publication Critical patent/UA114592C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/05—Oxidoreductases acting on NADH or NADPH (1.6) with a quinone or similar compound as acceptor (1.6.5)
    • C12Y106/05003—NADH dehydrogenase (ubiquinone) (1.6.5.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Винахід стосується пептиду ND2, що містить до 20 залишків, що містять залишки 310-321 пептиду ND2, якими пептид ND2 інгібує взаємодію з Src. Винахід також стосується способу лікування або здійснення профілактики інсульту пацієнту, що страждає або перебуває в групі ризику неврологічного порушення, та способу лікування або здійснення профілактики запального або невропатичного болю пацієнту, що страждає або перебуває в групі ризику розвитку невропатичного болю, за допомогою даного пептиду.
UAA201305474A 2010-09-28 2011-09-28 Пептид nd2 та спосіб лікування неврологічного захворювання UA114592C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38743910P 2010-09-28 2010-09-28
PCT/US2011/053764 WO2012050921A2 (en) 2010-09-28 2011-09-28 Nd2 peptides and methods of treating neurological disease

Publications (1)

Publication Number Publication Date
UA114592C2 true UA114592C2 (uk) 2017-07-10

Family

ID=45938878

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201305474A UA114592C2 (uk) 2010-09-28 2011-09-28 Пептид nd2 та спосіб лікування неврологічного захворювання

Country Status (15)

Country Link
US (1) US9073976B2 (uk)
EP (1) EP2621945B1 (uk)
JP (1) JP6073230B2 (uk)
KR (1) KR101893473B1 (uk)
CN (1) CN103282379B (uk)
AU (1) AU2011314074B2 (uk)
BR (1) BR112013007557A2 (uk)
CA (1) CA2812948C (uk)
DK (1) DK2621945T3 (uk)
IL (1) IL225464B (uk)
MX (1) MX343366B (uk)
RU (1) RU2607033C2 (uk)
SG (1) SG189104A1 (uk)
UA (1) UA114592C2 (uk)
WO (1) WO2012050921A2 (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016015457A (es) * 2014-05-28 2017-06-30 Nono Inc Sal de cloruro de tat-nr2b9c.
WO2017147298A1 (en) * 2016-02-23 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Peptide-based methods for treating neurological injury
JP6818871B2 (ja) * 2016-04-27 2021-01-20 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CN111499717B (zh) * 2020-04-10 2020-11-24 南京市儿童医院 一种脑源肽及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1007638T3 (da) * 1997-08-12 2007-05-21 Bristol Myers Squibb Co KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf
WO2000056880A1 (en) 1999-03-19 2000-09-28 Human Genome Sciences, Inc. 50 human secreted proteins
PL228041B1 (pl) * 2001-01-05 2018-02-28 Amgen Fremont Inc Przeciwciało przeciwko receptorowi insulinopodobnego czynnika wzrostu I, zawierajaca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana czasteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierze transgeniczne.
NZ538715A (en) * 2002-08-14 2007-07-27 Vertex Pharma Protein kinase inhibitors and uses thereof
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
US8003609B2 (en) * 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
US7425540B2 (en) * 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src
AU2006261342B2 (en) * 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N

Also Published As

Publication number Publication date
JP6073230B2 (ja) 2017-02-01
WO2012050921A3 (en) 2012-07-05
RU2013119830A (ru) 2014-11-10
CA2812948C (en) 2019-01-22
AU2011314074B2 (en) 2015-11-12
IL225464B (en) 2018-03-29
KR101893473B1 (ko) 2018-08-30
US20140274906A1 (en) 2014-09-18
DK2621945T3 (en) 2018-05-22
EP2621945A4 (en) 2014-05-07
AU2011314074A1 (en) 2013-05-09
EP2621945B1 (en) 2018-04-11
CN103282379A (zh) 2013-09-04
WO2012050921A2 (en) 2012-04-19
MX2013003330A (es) 2013-09-26
CN103282379B (zh) 2016-01-06
JP2014505655A (ja) 2014-03-06
CA2812948A1 (en) 2012-04-19
EP2621945A2 (en) 2013-08-07
BR112013007557A2 (pt) 2021-05-11
SG189104A1 (en) 2013-05-31
IL225464A0 (en) 2013-06-27
MX343366B (es) 2016-11-01
US9073976B2 (en) 2015-07-07
KR20140048070A (ko) 2014-04-23
RU2607033C2 (ru) 2017-01-10

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
EA201290557A1 (ru) Пептидный аналог оксинтомодулина
CY1121419T1 (el) Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης
MY181969A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
MY166776A (en) Humanised anti-ctla4 antibodies
EA201300583A1 (ru) Вазопротективное и кардиопротективное противодиабетическое лечение
EA201070914A1 (ru) Применение ранолазина для лечения боли
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
GT200800098A (es) Anticuerpos anti mn y metodos para su utilización
MX355543B (es) Macrociclos peptidomiméticos.
MY149630A (en) Antibodies against amyloid-beta peptide
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
JO3246B1 (ar) اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
UA114592C2 (uk) Пептид nd2 та спосіб лікування неврологічного захворювання
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
EP3988673A3 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
EA201300128A1 (ru) Комбинированная фармацевтическая композиция и способы лечения заболеваний или состояний, связанных с нарушением функции сердечно-сосудистой системы